NCT04624113View on ClinicalTrials.gov

Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 14, 2021

Primary Completion Date

August 9, 2022

Study Completion Date

February 17, 2024

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Tazemetostat

Epizyme will supply the study agent, which will be provided free of charge to the patient.

DRUG

Pembrolizumab

Pembrolizumab is commercially available

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

Sponsors

Collaborators (1)

Epizyme, Inc.
All Listed Sponsors
collaborator

Epizyme, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04624113 - Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Biotech Hunter | Biotech Hunter